SG11201407400XA - V1a receptor agonists - Google Patents

V1a receptor agonists

Info

Publication number
SG11201407400XA
SG11201407400XA SG11201407400XA SG11201407400XA SG11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA
Authority
SG
Singapore
Prior art keywords
lllll
international
llll
california
pct
Prior art date
Application number
SG11201407400XA
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Geoffrey S Harris
Robert Felix Galyean
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of SG11201407400XA publication Critical patent/SG11201407400XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Polyesters Or Polycarbonates (AREA)
SG11201407400XA 2012-05-10 2013-05-09 V1a receptor agonists SG11201407400XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645558P 2012-05-10 2012-05-10
PCT/US2013/040414 WO2013170077A2 (en) 2012-05-10 2013-05-09 V1a receptor agonists

Publications (1)

Publication Number Publication Date
SG11201407400XA true SG11201407400XA (en) 2014-12-30

Family

ID=48652296

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407400XA SG11201407400XA (en) 2012-05-10 2013-05-09 V1a receptor agonists

Country Status (29)

Country Link
US (1) US9644000B2 (zh)
EP (1) EP2847210B1 (zh)
JP (1) JP6231554B2 (zh)
KR (1) KR102050356B1 (zh)
CN (1) CN104350065B (zh)
AR (1) AR091013A1 (zh)
AU (1) AU2013259393B2 (zh)
BR (1) BR112014027996B1 (zh)
CA (1) CA2871776C (zh)
DK (1) DK2847210T3 (zh)
ES (1) ES2571928T3 (zh)
HK (1) HK1205706A1 (zh)
HR (1) HRP20160468T1 (zh)
HU (1) HUE027519T2 (zh)
IL (1) IL235558A (zh)
JO (1) JO3109B1 (zh)
MX (1) MX353864B (zh)
MY (1) MY167248A (zh)
NZ (1) NZ701365A (zh)
PH (1) PH12014502510B1 (zh)
PL (1) PL2847210T3 (zh)
RS (1) RS54722B1 (zh)
RU (1) RU2634617C2 (zh)
SA (1) SA113340536B1 (zh)
SG (1) SG11201407400XA (zh)
SI (1) SI2847210T1 (zh)
TW (1) TWI632161B (zh)
WO (1) WO2013170077A2 (zh)
ZA (1) ZA201408172B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388214B2 (en) 2014-11-05 2016-07-12 Ferring B.V. V1A receptor agonists
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス,インコーポレイテッド 腹水の治療
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
CN109010795B (zh) * 2018-09-12 2021-10-22 南京康舟医药科技有限公司 醋酸特利加压素注射液以及其制备方法
BR112023000906A2 (pt) * 2020-07-17 2023-02-07 Pharmain Corp Agonista parcial do receptor v1a e método de uso
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
WO2024073451A1 (en) * 2022-09-30 2024-04-04 Ocelot Bio, Inc. Mixed vasopressin receptor agonist-antagonist for treating end-stage liver disease and complications associated thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226132A1 (en) * 1999-11-04 2002-07-31 Ortho-McNeil Pharmaceutical, Inc. Nonpeptide substituted benzothiazepines as vasopressin antagonists
EP1188443A1 (en) * 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
WO2007006688A1 (en) * 2005-07-14 2007-01-18 F. Hoffmann-La Roche Ag Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
RU2418801C2 (ru) * 2005-09-28 2011-05-20 Ф. Хоффманн-Ля Рош Аг Индол-3-ил-карбонил-азаспиропроизводные в качестве антагонистов рецептора вазопрессина
US8222202B2 (en) * 2006-02-13 2012-07-17 Ferring B.V. Use of peptidic vasopressin receptor agonists
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs

Also Published As

Publication number Publication date
HUE027519T2 (en) 2016-10-28
KR102050356B1 (ko) 2019-11-29
SA113340536B1 (ar) 2015-10-08
AU2013259393A1 (en) 2014-11-20
US20150126432A1 (en) 2015-05-07
RU2634617C2 (ru) 2017-11-02
JP6231554B2 (ja) 2017-11-15
IL235558A (en) 2017-07-31
AU2013259393B2 (en) 2017-02-02
NZ701365A (en) 2016-05-27
US9644000B2 (en) 2017-05-09
CA2871776A1 (en) 2013-11-14
SI2847210T1 (sl) 2016-06-30
HRP20160468T1 (hr) 2016-06-03
ES2571928T3 (es) 2016-05-27
KR20150008175A (ko) 2015-01-21
HK1205706A1 (zh) 2015-12-24
MY167248A (en) 2018-08-14
TW201348262A (zh) 2013-12-01
WO2013170077A3 (en) 2014-03-27
PH12014502510A1 (en) 2014-12-22
CA2871776C (en) 2021-09-07
EP2847210A2 (en) 2015-03-18
WO2013170077A2 (en) 2013-11-14
CN104350065A (zh) 2015-02-11
MX353864B (es) 2018-02-01
AR091013A1 (es) 2014-12-30
DK2847210T3 (en) 2016-05-02
RS54722B1 (en) 2016-08-31
MX2014013646A (es) 2015-03-03
IL235558A0 (en) 2015-01-29
TWI632161B (zh) 2018-08-11
JO3109B1 (ar) 2017-09-20
CN104350065B (zh) 2020-04-28
ZA201408172B (en) 2015-12-23
BR112014027996B1 (pt) 2021-07-27
RU2014143941A (ru) 2016-07-10
EP2847210B1 (en) 2016-02-17
PH12014502510B1 (en) 2014-12-22
JP2015518820A (ja) 2015-07-06
PL2847210T3 (pl) 2016-08-31
BR112014027996A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
SG11201407400XA (en) V1a receptor agonists
SG11201808625QA (en) SOLUBLE C5aR ANTAGONISTS
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201804674UA (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201407533SA (en) Antiviral compounds
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201408094YA (en) Neprilysin inhibitors
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201808163WA (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201809237RA (en) Oxaborole esters and uses thereof
SG11201408685WA (en) Antibacterial microelement chelates and the use thereof in animal feeds
SG11201901188VA (en) Metal powder feedstocks for additive manufacturing, and system and methods for producing the same